Search

Your search keyword '"R Makdassi"' showing total 19 results
Start Over Author "R Makdassi" Search Limiters Available in Library Collection
19 results on '"R Makdassi"'

1. Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study

Author

Dimitri Titeca-Beauport, Vincent Audard, Laurent Juillard, Marie-Noëlle Peraldi, Jean-François Subra, Eric Thervet, Jean-Michel Halimi, Thierry Lobbedez, Gabriel Choukroun, Mathilde Tamain, Marc Hazzan, Alexandre Ganea, Maité Daroux, Thomas Quemeneur, Dominique Guerrot, Pauline Caillard, Marie Essig, François Vrtovsnik, Jean-Michel Rebibou, Cécile Vigneau, R. Makdassi, Marion Rabant, Morgane Heitz, Vincent Vuiblet, Alexandre Hertig, Adnane Lamrani, Jonchère, Laurent, CHU Amiens-Picardie, CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Grenoble, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Rouen, Normandie Université (NU), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Clermont-Ferrand, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Ecotaxie, microenvironnement et développement lymphocytaire (EMily (UMR_S_1160 / U1160)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CHU Lille, Inserm, Université de Lille, Lille Inflammation Research International Center - U 995 [LIRIC], Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)], Cardiovasculaire, métabolisme, diabétologie et nutrition [CarMeN], Institut Mondor de Recherche Biomédicale [IMRB], Université Paris Descartes - Paris 5 [UPD5], Centre de Recherche en Cancérologie Nantes-Angers [CRCNA], Centre Hospitalier Universitaire de Reims [CHU Reims], Service de Néphrologie - Hémodialyses [CHU Clermont-Ferrand], Ecotaxie, microenvironnement et développement lymphocytaire [EMily (UMR_S_1160 / U1160)], CHU Henri Mondor [Créteil], Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), and Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Subjects
medicine.medical_specialty, Urinary system, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, lcsh:Medicine, Disease, Anti-Glomerular Basement Membrane Disease, Gastroenterology, survival, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Stage (cooking), Adverse effect, anti-GBM disease, 030203 arthritis & rheumatology, urogenital system, business.industry, ANCA, Mortality rate, lcsh:R, Glomerulonephritis, General Medicine, medicine.disease, infection, 3. Good health, age, [SDV] Life Sciences [q-bio], Bacteremia, business
Abstract

In patients presenting with anti-glomerular basement membrane (GBM) disease with advanced isolated kidney involvement, the benefit of intensive therapy remains controversial due to adverse events, particularly infection. We aim to describe the burden of severe infections (SI) (requiring hospitalization or intravenous antibiotics) and identify predictive factors of SI in a large cohort of patients with anti-GBM disease. Among the 201 patients (median [IQR] age, 53 [30&ndash, 71] years) included, 74 had pulmonary involvement and 127 isolated glomerulonephritis. A total of 161 SI occurred in 116 patients during the first year after diagnosis. These infections occurred during the early stage of care (median [IQR] time, 13 [8&ndash, 19] days after diagnosis) with mainly pulmonary (45%), catheter-associated bacteremia (22%) and urinary tract (21%) infections. In multivariable analysis, positive ANCA ([HR] 1.62, 95% [95% CI] 1.07&ndash, 2.44], p = 0.02) and age at diagnosis (HR [95% CI] 1.10 [1.00&ndash, 1.21], p = 0.047) remained independently associated with SI. Age-adjusted severe infection during the first three months was associated with an increased three-year mortality rate (HR [95% CI] 3.13 [1.24&ndash, 7.88], p = 0.01). Thus, SI is a common early complication in anti-GBM disease, particularly in the elderly and those with positive anti-neutrophil cytoplasmic antibodies (ANCA). No significant association was observed between immunosuppressive strategy and occurrence of SI.

Published
2020
Full Text
View/download PDF

2. Hématomes surrénaliens potentialisés par le Synacthène® (HSS)

Author

J. Vandwalle, Jacques Petit, Fabien Saint, N. Surga, R. Makdassi, and Gabriel Choukroun

Subjects
Gynecology, medicine.medical_specialty, business.industry, Urology, Medicine, business
Abstract

Resume Objectif Rapporter une serie d’hematomes surrenaliens spontanes sous Synacthene® et definir la prise en charge a court, moyen et long terme. Patients et methodes De janvier 2000 a decembre 2008, cinq patients (quatre hommes et une femme), d’âge moyen 47 ans, ont ete pris en charge pour hematomes surrenaliens spontanes chez des patients traites par Synacthene® pour lombosciatalgie documentee depuis 72 heures. La prise en charge associait une evaluation clinique, endocrinienne et radiologique. Resultats Quatre patients ont ete surveilles et un seul a necessite une prise en charge chirurgicale. Aucune tumeur surrenalienne n’a ete diagnostiquee lors du suivi avec un recul de deux ans (un a quatre). Deux patients etaient atteints d’un syndrome des antiphospholipides. Conclusion Les hematomes surrenaliens spontanes sont une pathologie rare, dont la prise en charge doit d’abord etre une surveillance clinique, biologique et morphologique. Le bilan endocrinien, immunologique et radiologique systematique doit rechercher une tumeur surrenalienne secretante ou non, et un syndrome des antiphospholipides.

Published
2010
Full Text
View/download PDF

4. Contents, Vol. 72, 1996

Author

Hiroshi Toma, L. Raffaele, V. Dalmastri, Filippo Salvati, Divyesh M. Bhatt, Hiroshi Ishida, Hikaru Sugimoto, Juan M. Gonzalez, Salih Hazar, J. Guiserix, Kyoko Kurose, V. Stefanović, Majed Odeh, Hiroshi Inuma, Kamberi Perparim, Nilwarangkur S, L. Perini, F. Locatelli, Peter Nilsson-Ehle, Shigeo Takebayashi, N. Seyrek, G. Paunović, Vivette D. D'Agati, J.C. Boulanger, Mohamed A. El-Shahawy, Smaragdi Antonopoulou, M. Dapporto, Hiroshi Mabuchi, Syuko Yamamoto, Hiroshi Kitamura, Yong Goo Kim, A.G. Brox, G. Erba, R. Margreiter, Hiroshi Osawa, Hiroyoshi Matsukura, M. Vedovato, Der-Cherng Tarng, Hiromichi Suzuki, Ching-Huai Huang, Constantinos A. Demopoulos, R.F. Gagnon, Yahya Sagliker, D Di Landro, M. Oh, Shuichi Hatakeyama, Panos Ziroyiannis, A. Michault, Masateru Kawabata, P. Finielz, I. Guarnori, R. Pérez-García, Satoru Tsunoda, Shinsuke Nomura, F. Malacarne, Zensuke Ota, Byung Kee Bang, G. Ricci, Per Kjellstrand, Sompong Ong-ajyooth, Y. Sagliker, Gengo Osawa, Mark W. Majesky, Tadashi Asami, Hideaki Yamabe, L.P.W.J. van den Heuvel, Young Ok Kim, F. Fabrizi, Satsuki Yamada, H.A. Jalil, Arie Oliven, Takao Kohsaka, Hans-Georg Classen, Arturo Borsatti, B. de Cagny, R. Mallmann, M. Lago, Christos Iatrou, Yoshiharu Hiratsuka, Tanekazu Harada, Luan D. Truong, Ank Nurol, Masaki Kobayashi, Watanachai Susaengrat, Yoshiko Fujita, G.F. Romagnoli, Saime Paydas, Rainer Nobiling, D. Oefner, J.P. Mallie, George Moustakas, Syunji Ishihara, Zhi-Hong Liu, Kogo Onodera, Sumalee Nimmannit, G. Devulder, Marian Klinger, J. Radivojević, Chairat Shayakul, P. Fievet, Susumu Inaba, Masaaki Nakayama, Akira Noguchi, B. Athmani, T. Dimitrov, Emine Kocabaş, Phannee Pidetcha, P. Fardelone, Fumihiko Hinoshita, Raja I. Zabaneh, Hiroshi Nihei, M. Hattori, C. Raimondi, Naoko Yusa, Todd S. Ing, Hirofumi Makino, Manuel Martinez-Maldonado, Kouichi Hirayama, Björn Holmquist, Jesús Montoliu, P. Gilli, Hirokazu Okada, Hisashi Ozasa, Mitsuaki Kaizuka, Stefan H. Jacobson, Ichiro Koni, C. Aichberger, Augusto Antonello, David J. Leehey, R. Makdassi, A.F. van Lieburg, Masami Matsumura, Osamu Sakai, I. Pejčić, Toshio Okada, Yoshiaki Fujimiya, Miwako Arai, Hans Thysell, Seunghun Lee, Yu-Li Cho, V. Djordjević, David P. Brooks, Chul Woo Yang, Huan-Sheng Chen, Makoto Katagiri, Julio Ramos, William J. Kimberling, Kosuke Ota, Jackson Joe Yium, Paritosh Tiwari, M. Andréjak, Gary E. Striker, G. Pontoriero, P. Vaillant, Tung-Po Huang, Roberto Barrios, A. Peco-Antić, H. Sonnenberg, Osamu Hotta, Kaoru Sakai, Prida Malasit, Chie Inoue, Liliane J. Striker, Kandemir Tolga, Lorenzo A. Calò, Scott O. Trerotola, Stephen V. Foster, PeterMaria Rob, Salvatore Cantaro, Yoshihiko Kanno, V. Stojanov, Ann M. Johnson, A. Fournier, F. Zhang, Kosaku Nitta, Alex W. Yu, Richard Skroeder, P. Dennis DePalma, Keitaro Yokoyama, W. Proesmans, G. Guerra, Koji Kawamura, Merit F. Gadallah, M. Gowrishankar, I. Cheong, Eiko Suzuki, Klaus Sack, Maria Golato, Silvana Favaro, Byung Kee Kim, S. Di Filippo, J. Gondry, Necmi Aksaray, Akira Yamada, D. Marcelli, Nobuo Watanabe, Adam Bahattin, Makoto Uchiyama, Michihiro Gotoh, E. Sestigiani, Naoto Yamaguchi, Patricia A. Gabow, Stawomir C. Zmonarski, C. Campieri, Kenichi Shikata, Kennichi Shiroto, Steven Foster, I. Constant, Katsuhiko Sudo, A. Giudicissi, Ulf Nilsson, L. Neri, Kunimasa Yan, Regina R. Verani, Shuichi Tomisawa, Je Hoon Lee, M. Avramović, Akpolat Tekin, Chih-Wei Yang, Stanistaw Miękisz, Mercè Borràs, Haruki Nagahana, A. Koenigsrainer, Jerzy W. Mozrzymas, S. Stefoni, M.L. Halperin, Margret Arnadottir, Sigeko Hara, Naoyuki Tamura, Tsutomu Takahashi, Ikuo Horigome, Hidehiko Kawato, M. Ramdane, Yoshio Taguma, Yukiyoshi Nakamura, Chege J. Mukuria, F. Anaya, Satoshi Iwabuchi, Jana Pindur, L.M. Ho, M. Zompatori, Tetsuo Shibata, Ettore Tresca, V.V.A.M. Knoers, Touru Nishihara, L.A.H. Monnens, Ichiro Kajiwara, Akio Koyama, M. Crepaldi, Yoshindo Kawaguchi, Youji Ogawa, M.S. Garcia de Vinuesa, J.M. Hoarau, Shigeru Horita, Scott J. Savader, Wadi N. Suki, Bedir Abdülkerim, E. Lobjoie, Yuki Sakai, Hiroaki Muramoto, Andrzej Teisseyre, Han-Nan Liu, Tun-Jun Tsai, G. Bacchini, Hitoshi Ebata, Yung-Ming Chen, E. De Paoli Vitali, D. Toncheva, M. Kostić, Maria José Panadés, E. David, F. Valderrábano, Monica Rizzolo, Mario Liani, Yosuke Ogura, G.K. Richards, Catherine I. Lai, Angela D'Angelo, Nobuhide Mimura, Takao Saruta, Masaru Nasu, V. Bonomini, Neslihan Seyrek, Yoshio Suzuki, Somkiat Vasuvattakul, V. Parezanović, Theodore P. Labus, Masaharu Naiki, Shaul G. Massry, Yasuo Magari, S. Paydas, and Ryokichi Yasumori

Subjects
Traditional medicine, business.industry, Medicine, business
Published
1996
Full Text
View/download PDF

6. Subject Index Vol. 72, 1996

Author

P. Fardelone, Naoko Yusa, Hirokazu Okada, J. Gondry, N. Seyrek, Hiroshi Mabuchi, D Di Landro, Michihiro Gotoh, Patricia A. Gabow, Per Kjellstrand, Ichiro Koni, Osamu Hotta, Naoyuki Tamura, Hiroshi Toma, Stephen V. Foster, Julio Ramos, V. Bonomini, M. Andréjak, Nilwarangkur S, Stawomir C. Zmonarski, Somkiat Vasuvattakul, Ikuo Horigome, Hidehiko Kawato, L. Raffaele, Toshio Okada, Satoshi Iwabuchi, Keitaro Yokoyama, Neslihan Seyrek, Masateru Kawabata, Yahya Sagliker, Seunghun Lee, Yung-Ming Chen, D. Toncheva, P. Finielz, Kennichi Shiroto, M. Zompatori, Yong Goo Kim, Masaaki Nakayama, M. Crepaldi, Yoshindo Kawaguchi, Yoshiharu Hiratsuka, L. Neri, I. Cheong, Eiko Suzuki, A. Michault, V. Dalmastri, R. Margreiter, Shinsuke Nomura, R. Makdassi, Maria Golato, Kosuke Ota, Scott J. Savader, R. Mallmann, Maria José Panadés, M.S. Garcia de Vinuesa, Hiroshi Osawa, Wadi N. Suki, Yoshiaki Fujimiya, M. Vedovato, T. Dimitrov, Sigeko Hara, Emine Kocabaş, Akpolat Tekin, M. Avramović, Der-Cherng Tarng, A. Giudicissi, Fumihiko Hinoshita, Chih-Wei Yang, Yoshio Suzuki, Regina R. Verani, H. Sonnenberg, Takao Kohsaka, Watanachai Susaengrat, Hiromichi Suzuki, F. Malacarne, Tsutomu Takahashi, Prida Malasit, Chie Inoue, Kandemir Tolga, Lorenzo A. Calò, F. Locatelli, Tun-Jun Tsai, Han-Nan Liu, Augusto Antonello, David J. Leehey, A. Fournier, Mercè Borràs, PeterMaria Rob, F. Zhang, F. Fabrizi, E. De Paoli Vitali, Masami Matsumura, Juan M. Gonzalez, Salih Hazar, J. Guiserix, Raja I. Zabaneh, M. Kostić, George Moustakas, Syunji Ishihara, Chul Woo Yang, B. Athmani, Salvatore Cantaro, Rainer Nobiling, D. Oefner, P. Gilli, Kogo Onodera, Chege J. Mukuria, Y. Sagliker, Vivette D. D'Agati, Shigeo Takebayashi, Hans-Georg Classen, Phannee Pidetcha, M. Hattori, G. Paunović, G.K. Richards, P. Dennis DePalma, Todd S. Ing, Catherine I. Lai, Angela D'Angelo, Hiroshi Kitamura, Zhi-Hong Liu, F. Anaya, Hisashi Ozasa, Mitsuaki Kaizuka, Byung Kee Bang, Christos Iatrou, V. Parezanović, Yoshiko Fujita, G.F. Romagnoli, Mario Liani, Makoto Katagiri, Theodore P. Labus, David P. Brooks, Majed Odeh, Masaru Nasu, Koji Kawamura, A. Peco-Antić, Tanekazu Harada, Kosaku Nitta, Nobuhide Mimura, Liliane J. Striker, I. Guarnori, Syuko Yamamoto, Gengo Osawa, Arturo Borsatti, Ann M. Johnson, Zensuke Ota, Filippo Salvati, Alex W. Yu, Hirofumi Makino, Takao Saruta, Richard Skroeder, Divyesh M. Bhatt, G. Ricci, Masaki Kobayashi, C. Raimondi, L.P.W.J. van den Heuvel, Akira Yamada, C. Aichberger, Young Ok Kim, Kamberi Perparim, Youji Ogawa, Chairat Shayakul, P. Fievet, Hikaru Sugimoto, Necmi Aksaray, D. Marcelli, Osamu Sakai, Ulf Nilsson, Huan-Sheng Chen, Shigeru Horita, Björn Holmquist, Naoto Yamaguchi, E. Lobjoie, Steven Foster, L. Perini, G. Guerra, M. Gowrishankar, Masaharu Naiki, Luan D. Truong, Ank Nurol, Haruki Nagahana, A.F. van Lieburg, Mohamed A. El-Shahawy, Merit F. Gadallah, Hiroshi Inuma, Kaoru Sakai, Kenichi Shikata, Shuichi Tomisawa, Je Hoon Lee, Ching-Huai Huang, Miwako Arai, S. Di Filippo, Stanistaw Miękisz, Constantinos A. Demopoulos, Kouichi Hirayama, R.F. Gagnon, Nobuo Watanabe, G. Pontoriero, Adam Bahattin, Roberto Barrios, P. Vaillant, Makoto Uchiyama, Hiroshi Ishida, Mark W. Majesky, A.G. Brox, G. Erba, Tung-Po Huang, E. Sestigiani, Tadashi Asami, Kunimasa Yan, R. Pérez-García, M. Ramdane, Yoshio Taguma, Yukiyoshi Nakamura, C. Campieri, Shaul G. Massry, Scott O. Trerotola, Satsuki Yamada, Yasuo Magari, Yoshihiko Kanno, S. Paydas, Jana Pindur, L.M. Ho, Peter Nilsson-Ehle, Smaragdi Antonopoulou, W. Proesmans, J. Radivojević, H.A. Jalil, Yu-Li Cho, Ettore Tresca, V.V.A.M. Knoers, Ryokichi Yasumori, J.P. Mallie, Jackson Joe Yium, Byung Kee Kim, Paritosh Tiwari, Kyoko Kurose, V. Stojanov, Hiroyoshi Matsukura, J.M. Hoarau, Silvana Favaro, Bedir Abdülkerim, Hitoshi Ebata, Yuki Sakai, Hiroaki Muramoto, Andrzej Teisseyre, G. Bacchini, Klaus Sack, E. David, I. Constant, F. Valderrábano, Monica Rizzolo, Katsuhiko Sudo, Yosuke Ogura, A. Koenigsrainer, Jerzy W. Mozrzymas, S. Stefoni, M.L. Halperin, Margret Arnadottir, M. Dapporto, Satoru Tsunoda, Arie Oliven, V. Djordjević, I. Pejčić, William J. Kimberling, Gary E. Striker, M. Oh, Shuichi Hatakeyama, Hideaki Yamabe, M. Lago, Akira Noguchi, Tetsuo Shibata, Saime Paydas, Hiroshi Nihei, Sumalee Nimmannit, G. Devulder, Marian Klinger, Susumu Inaba, Touru Nishihara, L.A.H. Monnens, Hans Thysell, V. Stefanović, J.C. Boulanger, Ichiro Kajiwara, Akio Koyama, Jesús Montoliu, Panos Ziroyiannis, Stefan H. Jacobson, Sompong Ong-ajyooth, Manuel Martinez-Maldonado, and B. de Cagny

Subjects
Index (economics), business.industry, Statistics, Medicine, Subject (documents), business
Published
1996
Full Text
View/download PDF

8. A search for Pneumocystis carinii DNA by polymerase chain reaction on bronchoalveolar lavage fluids from patients with Wegener's granulomatosis

Author

Vincent Jounieaux, Christian Raccurt, A. Totet, R. Makdassi, G. Nevez, and A. Pruna

Subjects
Wegener s, Adult, Male, medicine.diagnostic_test, Pneumocystis carinii DNA, business.industry, Pneumocystis, Pneumonia, Pneumocystis, Granulomatosis with Polyangiitis, Middle Aged, Polymerase Chain Reaction, law.invention, Microbiology, Bronchoalveolar lavage, Rheumatology, law, Wegener granulomatosis, medicine, Humans, Pharmacology (medical), Female, business, DNA, Fungal, Bronchoalveolar Lavage Fluid, Polymerase chain reaction
Published
1999

11. Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients

Author

M.S. Moukhtar, Tolani M, Claude Desplan, C Calmette, R. Makdassi, Sebert Jl, J D Gheerbrant, Fournier A, Andrejak M, and Coevoet B

Subjects
Adult, Calcitonin, Male, medicine.medical_specialty, Parathyroid hormone, Propranolol, Pharmacology, Propanolamines, Heart Rate, Internal medicine, medicine, Humans, Renal osteodystrophy, General Environmental Science, Metoprolol, Uremia, business.industry, General Engineering, General Medicine, Calcitonin secretion, medicine.disease, Endocrinology, Parathyroid Hormone, General Earth and Planetary Sciences, Female, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Hormone, Research Article
Abstract

Nine uraemic patients not being treated by dialysis received intravenous propranolol 1 microgram/kg/min for 85 minutes after a priming dose of 1 mg. Fifteen days later, six of them received intravenous metoprolol 1.2 microgram/kg/min after a priming dose of 1.2 mg. Plasma concentrations of parathyroid hormone (PTH) and calcitonin fell significantly after propranolol but not after metoprolol, whereas no change in plasma concentrations of ionised calcium and phosphate occurred with either drug. Heart rate fell similarly with both drugs. The fact that propranolol acutely suppressed PTH and calcitonin secretion in uraemic patients indicates that further studies are warranted to assess the long-term effects of the drug on the secretion of these hormones and on renal osteodystrophy. The contrast between the responses to propranolol and metoprolol supports the concept that PTH and calcitonin secretion is modulated through specific beta 2-receptors.

Published
1980

12. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease.

Author

Caillard P, Vigneau C, Halimi JM, Hazzan M, Thervet E, Heitz M, Juillard L, Audard V, Rabant M, Hertig A, Subra JF, Vuiblet V, Guerrot D, Tamain M, Essig M, Lobbedez T, Quemeneur T, Legendre M, Ganea A, Peraldi MN, Vrtovsnik F, Daroux M, Makdassi R, Choukroun G, and Titeca-Beauport D

Subjects
Male, Humans, Female, Prognosis, Complement C3 analysis, Retrospective Studies, Kidney pathology, Anti-Glomerular Basement Membrane Disease complications
Abstract

Background and Objectives: Activation of the complement system is involved in the pathogenesis of anti-glomerular basement membrane (anti-GBM) disease. Glomerular deposits of complement 3 (C3) are often detected on kidney biopsies. The primary objective of this study was to analyze the prognostic value of the serum C3 level and the presence of C3 glomerular deposits in patients with anti-GBM disease., Methods: We conducted a retrospective cohort study of 150 single-positive patients with anti-GBM disease diagnosed between 1997 and 2017. Patients were categorized according to the serum C3 level (forming a low C3 (C3<1.23 g/L) and a high C3 (C3≥1.23 g/L) groups) and positivity for C3 glomerular staining (forming the C3+ and C3- groups). The main outcomes were kidney survival and patient survival., Results: Of the 150 patients included, 89 (65%) were men. The median [interquartile range (IQR)] age was 45 [26-64]. At diagnosis, kidney involvement was characterized by a median [IQR] peak serum creatinine (SCr) level of 578 [298-977] µmol/L, and 106 (71%) patients required dialysis. Patients in the low C3 group (72 patients) had more severe kidney disease at presentation, as characterized by higher prevalences of oligoanuria, peak SCr ≥500 µmol/L (69%, vs. 53% in the high C3 group; p=0.03), nephrotic syndrome (42%, vs. 24%, respectively; p=0.02) and fibrous forms on the kidney biopsy (21%, vs. 8%, respectively; p=0.04). Similarly, we observed a negative association between the presence of C3 glomerular deposits (in 52 (41%) patients) and the prevalence of cellular forms (83%, vs. 58% in the C3- group; p=0.003) and acute tubulo-interstitial lesions (60%, vs. 36% in the C3- group; p=0.007). When considering patients not on dialysis at diagnosis, the kidney survival rate at 12 months was poorer in the C3+ group (50% [25-76], vs. 91% [78-100] in the C3- group; p=0.01), with a hazard ratio [95% confidence interval] of 5.71 [1.13-28.85] (p=0.04, after adjusting for SCr)., Conclusion: In patients with anti-GBM disease, a low serum C3 level and the presence of C3 glomerular deposits were associated with more severe disease and histological kidney involvement at diagnosis. In patients not on dialysis at diagnosis, the presence of C3 deposits was associated with worse kidney survival., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Caillard, Vigneau, Halimi, Hazzan, Thervet, Heitz, Juillard, Audard, Rabant, Hertig, Subra, Vuiblet, Guerrot, Tamain, Essig, Lobbedez, Quemeneur, Legendre, Ganea, Peraldi, Vrtovsnik, Daroux, Makdassi, Choukroun and Titeca-Beauport.)

Published
2023
Full Text
View/download PDF

13. Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study.

Author

Caillard P, Vigneau C, Halimi JM, Hazzan M, Thervet E, Heitz M, Juillard L, Audard V, Rabant M, Hertig A, Subra JF, Vuiblet V, Guerrot D, Tamain M, Essig M, Lobbedez T, Quemeneur T, Rebibou JM, Ganea A, Peraldi MN, Vrtovsnik F, Daroux M, Lamrani A, Makdassi R, Choukroun G, and Titeca-Beauport D

Abstract

In patients presenting with anti-glomerular basement membrane (GBM) disease with advanced isolated kidney involvement, the benefit of intensive therapy remains controversial due to adverse events, particularly infection. We aim to describe the burden of severe infections (SI) (requiring hospitalization or intravenous antibiotics) and identify predictive factors of SI in a large cohort of patients with anti-GBM disease. Among the 201 patients (median [IQR] age, 53 [30-71] years) included, 74 had pulmonary involvement and 127 isolated glomerulonephritis. A total of 161 SI occurred in 116 patients during the first year after diagnosis. These infections occurred during the early stage of care (median [IQR] time, 13 [8-19] days after diagnosis) with mainly pulmonary (45%), catheter-associated bacteremia (22%) and urinary tract (21%) infections. In multivariable analysis, positive ANCA (HR [95\% CI] 1.62 [1.07--2.44]; p = 0.02) and age at diagnosis (HR [95% CI] 1.10 [1.00-1.21]; p = 0.047) remained independently associated with SI. Age-adjusted severe infection during the first three months was associated with an increased three-year mortality rate (HR [95% CI] 3.13 [1.24-7.88]; p = 0.01). Thus, SI is a common early complication in anti-GBM disease, particularly in the elderly and those with positive anti-neutrophil cytoplasmic antibodies (ANCA). No significant association was observed between immunosuppressive strategy and occurrence of SI.

Published
2020
Full Text
View/download PDF

14. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Author

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, and Frémeaux-Bacchi V

Subjects
Adolescent, Adult, Aged, Atypical Hemolytic Uremic Syndrome physiopathology, Child, Child, Preschool, Complement Factor H genetics, Female, Follow-Up Studies, Humans, Male, Membrane Cofactor Protein genetics, Middle Aged, Recurrence, Withholding Treatment, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Atypical Hemolytic Uremic Syndrome drug therapy, Atypical Hemolytic Uremic Syndrome genetics, Complement System Proteins genetics
Abstract

Background and Objectives: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal duration of eculizumab treatment in atypical hemolytic uremic syndrome remains debated. We report on the French atypical hemolytic uremic syndrome working group's first 2-year experience with eculizumab discontinuation in patients with atypical hemolytic uremic syndrome., Design, Setting, Participants & Measurements: Using the French atypical hemolytic uremic syndrome registry database, we retrospectively identified all dialysis-free patients with atypical hemolytic uremic syndrome who discontinued eculizumab between 2010 and 2014 and reviewed their relevant clinical and biologic data. The decision to discontinue eculizumab was made by the clinician in charge of the patient. All patients were closely monitored by regular urine dipsticks and blood tests. Eculizumab was rapidly (24-48 hours) restarted in case of relapse., Results: Among 108 patients treated with eculizumab, 38 patients (nine children and 29 adults) discontinued eculizumab (median treatment duration of 17.5 months). Twenty-one patients (55%) carried novel or rare complement genes variants. Renal recovery under eculizumab was equally good in patients with and those without complement gene variants detected. After a median follow-up of 22 months, 12 patients (31%) experienced atypical hemolytic uremic syndrome relapse. Eight of 11 patients (72%) with complement factor H variants, four of eight patients (50%) with membrane cofactor protein variants, and zero of 16 patients with no rare variant detected relapsed. In relapsing patients, early reintroduction (≤48 hours) of eculizumab led to rapid (<7 days) hematologic remission and a return of serum creatinine to baseline level in a median time of 26 days. At last follow-up, renal function remained unchanged in nonrelapsing and relapsing patients compared with baseline values before eculizumab discontinuation., Conclusions: Pathogenic variants in complement genes were associated with higher risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Prospective studies are needed to identify biomarkers predictive of relapse and determine the best strategy of retreatment in relapsing patients., (Copyright © 2016 by the American Society of Nephrology.)

Published
2017
Full Text
View/download PDF

15. Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.

Author

Zaidan M, Terrier B, Pozdzik A, Frouget T, Rioux-Leclercq N, Combe C, Lepreux S, Hummel A, Noël LH, Marie I, Legallicier B, François A, Huart A, Launay D, Kaplanski G, Bridoux F, Vanhille P, Makdassi R, Augusto JF, Rouvier P, Karras A, Jouanneau C, Verpont MC, Callard P, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Saadoun D, Ronco P, Brochériou I, Cacoub P, and Plaisier E

Subjects
Cyclophosphamide therapeutic use, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Prognosis, Retrospective Studies, Rituximab therapeutic use, Cryoglobulinemia complications, Cryoglobulinemia diagnosis, Cryoglobulinemia drug therapy, Glomerulonephritis, Membranoproliferative complications, Glomerulonephritis, Membranoproliferative diagnosis, Glomerulonephritis, Membranoproliferative drug therapy
Abstract

Noninfectious mixed cryoglobulinemic GN (MCGN) has been poorly investigated. We analyzed presentation and outcome of 80 patients with biopsy-proven MCGN, which were identified in the retrospective French CryoVas survey. MCGN was related to primary Sjögren's syndrome in 22.5% of patients and to lymphoproliferative disorders in 28.7% of patients, and was defined as essential in 48.8% of patients. At presentation, hematuria, proteinuria ≥1 g/d, hypertension, and renal failure were observed in 97.4%, 84.8%, 85.3%, and 82.3% of cases, respectively. Mean±eGFR was 39.5±20.4 ml/min per 1.73 m(2) Membranoproliferative GN was the predominant histologic pattern, observed in 89.6% of cases. Renal interstitium inflammatory infiltrates were observed in 50% of cases. First-line treatment consisted of steroids alone (27.6%) or in association with rituximab (21.1%), alkylating agents (36.8%) or a combination of cyclophosphamide and rituximab (10.5%). After a mean follow-up of 49.9±45.5 months, 42.7% of patients relapsed with a renal flare in 75% of cases. At last follow-up, mean eGFR was 50.2±26.1 ml/min per 1.73 m(2)with 9% of patients having reached ESRD; 59% and 50% of patients achieved complete clinical and renal remission, respectively. A rituximab+steroids regimen prevented relapses more effectively than steroids alone or a cyclophosphamide+steroids combination did, but was associated with a higher rate of early death when used as first-line therapy. Severe infections and new-onset B-cell lymphoma occurred in 29.1% and 8.9% of cases, respectively; 24% of patients died. In conclusion, noninfectious MCGN has a poor long-term outcome with severe infections as the main cause of death., (Copyright © 2016 by the American Society of Nephrology.)

Published
2016
Full Text
View/download PDF

16. A search for Pneumocystis carinii DNA by polymerase chain reaction on bronchoalveolar lavage fluids from patients with Wegener's granulomatosis.

Author

Nevez G, Pruna A, Jounieaux V, Makdassi R, Totet A, and Raccurt C

Subjects
Adult, Female, Humans, Male, Middle Aged, Pneumocystis genetics, Polymerase Chain Reaction, Bronchoalveolar Lavage Fluid microbiology, DNA, Fungal analysis, Granulomatosis with Polyangiitis microbiology, Pneumocystis isolation & purification, Pneumonia, Pneumocystis diagnosis
Published
1999
Full Text
View/download PDF

18. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies.

Author

Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, Noel LH, Ronco PM, and Aucouturier P

Subjects
Adjuvants, Immunologic metabolism, Adult, Aged, Aged, 80 and over, Antigen-Antibody Reactions, Cathepsin B immunology, Fanconi Syndrome metabolism, Female, Humans, Immunoglobulin Light Chains isolation & purification, Kidney Diseases enzymology, Kidney Diseases etiology, Kidney Diseases immunology, Male, Middle Aged, Mucoproteins metabolism, Myeloma Proteins immunology, Pepsin A immunology, Uromodulin, Cathepsin B metabolism, Immunoglobulin Light Chains metabolism, Kidney Diseases metabolism, Kidney Tubules, Multiple Myeloma complications, Myeloma Proteins metabolism, Pepsin A metabolism
Abstract

Kidney tubule dysfunction and lesions are frequent complications of myeloma, related to unknown properties of the monoclonal light chain. We have analyzed protease sensitivity and binding properties of urinary light chains from four patients with Fanconi's syndrome, 12 with cast nephropathy, and four control patients without myeloma-associated tubulopathy. All light chains were normal-sized, monomeric and/or dimeric, and none was N-glycosylated. Kinetic studies of light chain digestion by pepsin and the lysosomal enzyme cathepsin B showed the generation of a protease-resistant 12 kDa fragment, corresponding to the V domain of the kappa chain in the four Fanconi's syndrome patients; in two out of four the V domain was also completely resistant to trypsin. Western and dot blots revealed similar patterns of reactivity of light chains from patients with the Fanconi's syndrome towards other light chains. Properties of cast-nephropathy light chains were more heterogeneous but clearly differed from those of Fanconi's syndrome: (i) 9 out of 12 were of the lambda-type; (ii) only four yielded a transient 12 kDa fragment after cathepsin B digestion, but all showed some resistance to proteolysis of the entire molecule or a fragment thereof to at least one protease, at variance with control light chains; (iii) they displayed various patterns of reactivity with other light chains; (iv) 7 out of 12 reacted specifically with Tamm-Horsfall protein (THP) by ELISA, in contrast with those of Fanconi's syndrome. In one patient who presented with cast nephropathy and the Fanconi's syndrome, the light chain exhibited both partial resistance of the V kappa domain to cathepsin B and the highest reactivity with THP.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1995
Full Text
View/download PDF

19. Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.

Author

Coevoet B, Desplan C, Sebert JL, Makdassi R, Andrejak M, Gheerbrant JD, Tolani M, Calmette C, Moukhtar MS, and Fournier A

Subjects
Adult, Female, Heart Rate drug effects, Humans, Male, Uremia blood, Calcitonin blood, Metoprolol therapeutic use, Parathyroid Hormone blood, Propanolamines therapeutic use, Propranolol therapeutic use, Uremia drug therapy
Abstract

Nine uraemic patients not being treated by dialysis received intravenous propranolol 1 microgram/kg/min for 85 minutes after a priming dose of 1 mg. Fifteen days later, six of them received intravenous metoprolol 1.2 microgram/kg/min after a priming dose of 1.2 mg. Plasma concentrations of parathyroid hormone (PTH) and calcitonin fell significantly after propranolol but not after metoprolol, whereas no change in plasma concentrations of ionised calcium and phosphate occurred with either drug. Heart rate fell similarly with both drugs. The fact that propranolol acutely suppressed PTH and calcitonin secretion in uraemic patients indicates that further studies are warranted to assess the long-term effects of the drug on the secretion of these hormones and on renal osteodystrophy. The contrast between the responses to propranolol and metoprolol supports the concept that PTH and calcitonin secretion is modulated through specific beta 2-receptors.

Published
1980
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results